| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c589d006869805d02ef91b204ba660e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c1f7031a0a7df6f5148e9d259240dd21 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1203 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 |
| filingDate |
2021-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b9e8f54b27ec851a9167a13f6266909
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ad3e70602e39376a3bfbf406e7eaf2d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be2fc2f47ca83c5eab85e8f13a17540d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1a49d51fc90514a0b8d823e5d74524b |
| publicationDate |
2021-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2021100512-A4 |
| titleOfInvention |
A Helicobacter Pylori B Cell Tolerance Epitope and Its Prepared Antibody |
| abstract |
The present invention discloses a Helicobacter pylori B cell tolerance epitope and a monoclonal nantibody prepared by using this epitope, which can be used for the treatment of infected persons with nthe presence of natural immune tolerance to Helicobacter pylori, or for the prevention of infant with nmaternal vertical transmission but without established infection. The present invention has the nadvantages including less side effects, good patient compliance, easy large-scale production and etc. |
| priorityDate |
2020-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |